SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today
BioCardia (BCDA) Reports Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Observed a Confirmed Complete Response in the First Patient and a Best Overall Response of Stable Disease in Two Additional Patients in the Lowest-Dose Cohort; Anticipate Interim Data in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Monotherapy Enrollment Complete; Antici.
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.